179
Views
3
CrossRef citations to date
0
Altmetric
Mechanisms

Peripheral killer cells do not differentiate between asthma patients with or without fixed airway obstruction

, PhD, , PhD, , MBBS, FRCP, DM, , PhD, , PhD & , PhD
Pages 456-466 | Received 02 May 2016, Accepted 10 Sep 2016, Published online: 21 Dec 2016

References

  • Ferkol T, Schraufnagel D. The global burden of respiratory disease. Ann Am Thorac Soc 2014;11:404–406.
  • Romanet-Manent S, Charpin D, Magnan A, Lanteaume A, Vervloet D, Group EC. Allergic vs nonallergic asthma: what makes the difference? Allergy 2002;57:607–613.
  • Agache I, Akdis C, Jutel M, Virchow JC. Untangling asthma phenotypes and endotypes. Allergy 2012;67:835–846.
  • Corren J. Asthma phenotypes and endotypes: an evolving paradigm for classification. Discov Med 2013;15:243–249.
  • George BJ, Reif DM, Gallagher JE, Williams-DeVane CR, Heidenfelder BL, Hudgens EE, et al. Data-driven asthma endotypes defined from blood biomarker and gene expression data. PLoS One 2015;10:e0117445.
  • Bell MC, Busse WW. Is it asthma or is it COPD: the overlap syndrome. J Allergy Clin Immunol Pract 2015;3:641–642; quiz 643.
  • Tamada T, Sugiura H, Takahashi T, Matsunaga K, Kimura K, Katsumata U, Takekoshi D, Kikuchi T, Ohta K, Ichinose M. Biomarker-based detection of asthma-COPD overlap syndrome in COPD populations. Int J Chron Obstruct Pulmon Dis 2015;10:2169–2176.
  • Vanfleteren LE, Kocks JW, Stone IS, Breyer-Kohansal R, Greulich T, Lacedonia D, et al. Moving from the Oslerian paradigm to the post-genomic era: are asthma and COPD outdated terms? Thorax 2014;69:72–79.
  • Boulet LP, Turcotte H, Turcot O, Chakir J. Airway inflammation in asthma with incomplete reversibility of airflow obstruction. Respir Med 2003; 97:739–744.
  • Bumbacea D, Campbell D, Nguyen L, Carr D, Barnes PJ, Robinson D, et al. Parameters associated with persistent airflow obstruction in chronic severe asthma. Eur Respir J 2004;24:122–128.
  • Di Lorenzo G, Mansueto P, Ditta V, Esposito-Pellitteri M, Lo Bianco C, Leto-Barone MS, et al. Similarity and differences in elderly patients with fixed airflow obstruction by asthma and by chronic obstructive pulmonary disease. Respir Med 2008;102:232–238.
  • Fabbri LM, Romagnoli M, Corbetta L, Casoni G, Busljetic K, Turato G, et al. Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003;167:418–424.
  • Guerra S, Martinez FD: Epidemiology of the origins of airflow limitation in asthma. Proc Am Thorac Soc 2009;6:707–711.
  • Guerra S, Sherrill DL, Kurzius-Spencer M, Venker C, Halonen M, Quan SF, et al. The course of persistent airflow limitation in subjects with and without asthma. Respir Med 2008;102:1473–1482.
  • Lee JH, Haselkorn T, Borish L, Rasouliyan L, Chipps BE, Wenzel SE. Risk factors associated with persistent airflow limitation in severe or difficult-to-treat asthma: insights from the TENOR study. Chest 2007;132:1882–1889.
  • Selivanova PA, Kulikov ES, Kozina OV, Gereng EA, Freidin MB, Ogorodova LM: Morphological and molecular characteristics of “difficult” asthma. J Asthma 2010;47:269–275.
  • Shaw DE, Berry MA, Hargadon B, McKenna S, Shelley MJ, Green RH, et al. Association between neutrophilic airway inflammation and airflow limitation in adults with asthma. Chest 2007;132:1871–1875.
  • Tsoumakidou M, Tzanakis N, Kyriakou D, Chrysofakis G, Siafakas NM: Inflammatory cell profiles and T-lymphocyte subsets in chronic obstructive pulmonary disease and severe persistent asthma. Clin Exp Allergy 2004;34:234–240.
  • van Rensen EL, Sont JK, Evertse CE, Willems LN, Mauad T, Hiemstra PS, et al. Bronchial CD8 cell infiltrate and lung function decline in asthma. Am J Respir Crit Care Med 2005;172:837–841.
  • Vonk JM, Jongepier H, Panhuysen CI, Schouten JP, Bleecker ER, Postma DS: Risk factors associated with the presence of irreversible airflow limitation and reduced transfer coefficient in patients with asthma after 26 sources of follow up. Thorax 2003;58:322–327.
  • Fattahi F, Vonk JM, Bulkmans N, Fleischeuer R, Gouw A, Grunberg K, et al. Old dilemma: asthma with irreversible airway obstruction or COPD. Virchows Arch 2015;467:583–593.
  • Zhang L, He L, Gong J, Liu C. Risk factors associated with irreversible airway obstruction in asthma: a systematic review and meta-analysis. Biomed Res Int 2016;2016:9868704.
  • Tubby C, Harrison T, Todd I, Fairclough L. Immunological basis of reversible and fixed airways disease. Clin Sci 2011;121:285–296.
  • Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932–946.
  • Akbari O, Faul JL, Hoyte EG, Berry GJ, Wahlstrom J, Kronenberg M, et al. CD4+ invariant T-cell-receptor+ natural killer T cells in bronchial asthma. N Engl J Med 2006;354:1117–1129.
  • Betts RJ, Kemeny DM. CD8+ T cells in asthma: friend or foe? Pharmacol Ther 2009;121:123–131.
  • Culley FJ. Natural killer cells in infection and inflammation of the lung. Immunology 2009;128:151–163.
  • Godfrey DI, Kronenberg M. Going both ways: immune regulation via CD1d-dependent NKT cells. J Clin Invest 2004;114:1379–1388.
  • Kuylenstierna C, Bjorkstrom NK, Andersson SK, Sahlstrom P, Bosnjak L, Paquin-Proulx D, et al. NKG2D performs two functions in invariant NKT cells: direct TCR-independent activation of NK-like cytolysis and co-stimulation of activation by CD1d. Eur J Immunol 2011;41:1913–1923.
  • Lombardi V, Stock P, Singh AK, Kerzerho J, Yang W, Sullivan BA, et al. A CD1d-dependent antagonist inhibits the activation of invariant NKT cells and prevents development of allergen-induced airway hyperreactivity. J Immunol 2010;184:2107–2115.
  • Ple C, Barrier M, Amniai L, Marquillies P, Bertout J, Tsicopoulos A, et al. Natural killer cells accumulate in lung-draining lymph nodes and regulate airway eosinophilia in a murine model of asthma. Scand J Immunol 2010; 72:118–127.
  • Sakuishi K, Oki S, Araki M, Porcelli SA, Miyake S, Yamamura T. Invariant NKT cells biased for IL-5 production act as crucial regulators of inflammation. J Immunol 2007;179:3452–3462.
  • Stock P, Lombardi V, Kohlrautz V, Akbari O. Induction of airway hyperreactivity by IL-25 is dependent on a subset of invariant NKT cells expressing IL-17RB. J Immunol 2009;182:5116–5122.
  • Terashima A, Watarai H, Inoue S, Sekine E, Nakagawa R, Hase K, et al. A novel subset of mouse NKT cells bearing the IL-17 receptor B responds to IL-25 and contributes to airway hyperreactivity. J Exp Med 2008;205:2727–2733.
  • Wei H, Zhang J, Xiao W, Feng J, Sun R, Tian Z. Involvement of human natural killer cells in asthma pathogenesis: natural killer 2 cells in type 2 cytokine predominance. J Allergy Clin Immunol 2005;115:841–847.
  • Wingender G, Krebs P, Beutler B, Kronenberg M. Antigen-specific cytotoxicity by invariant NKT cells in vivo is CD95/CD178-dependent and is correlated with antigenic potency. J Immunol 2010;185:2721–2729.
  • Urbanowicz RA, Lamb JR, Todd I, Corne JM, Fairclough LC. Enhanced effector function of cytotoxic cells in the induced sputum of COPD patients. Respir Res 2010;11:76–84.
  • Kim EY, Battaile JT, Patel AC, You Y, Agapov E, Grayson MH, et al. Persistent activation of an innate immune response translates respiratory viral infection into chronic lung disease. Nat Med 2008;14:633–640.
  • Fairclough L, Urbanowicz RA, Corne J, Lamb JR. Killer cells in chronic obstructive pulmonary disease. Clin Sci (Lond) 2008;114:533–541.
  • Urbanowicz RA, Lamb JR, Todd I, Corne JM, Fairclough LC: Altered effector function of peripheral cytotoxic cells in COPD. Respir Res 2009;10:53–65.
  • GOLD: Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease; 2016. Available from http://goldcopd.org/global-strategy-diagnosis-management-prevention-copd-2016
  • Negm OH, Mannsperger HA, McDermott EM, Drewe E, Powell RJ, Todd I, et al. A pro-inflammatory signalome is constitutively activated by C33Y mutant TNF receptor 1 in TNF receptor-associated periodic syndrome (TRAPS). Eur J Immunol 2014;44:2096–2110.
  • Champagne P, Ogg GS, King AS, Knabenhans C, Ellefsen K, Nobile M, et al. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature 2001;410:106–111.
  • Lanier LL, Testi R, Bindl J, Phillips JH. Identity of Leu-19 (CD56) leukocyte differentiation antigen and neural cell adhesion molecule. J Exp Med 1989, 169:2233–2238.
  • Godfrey DI, Stankovic S, Baxter AG. Raising the NKT cell family. Nat Immunol 2010, 11:197–206.
  • Wang J, Urbanowicz RA, Tighe PJ, Todd I, Corne JM, Fairclough LC. Differential activation of killer cells in the circulation and the lung: a study of current smoking status and chronic obstructive pulmonary disease (COPD). PLoS One 2013;8:e58556.
  • Li C, Ge B, Nicotra M, Stern JN, Kopcow HD, Chen X, et al. JNK MAP kinase activation is required for MTOC and granule polarization in NKG2D-mediated NK cell cytotoxicity. Proc Natl Acad Sci USA 2008;105:3017–3022.
  • Chen X, Trivedi PP, Ge B, Krzewski K, Strominger JL. Many NK cell receptors activate ERK2 and JNK1 to trigger microtubule organizing center and granule polarization and cytotoxicity. Proc Natl Acad Sci USA 2007;104:6329–6334.
  • Liu W, Liang Q, Balzar S, Wenzel S, Gorska M, Alam R. Cell-specific activation profile of extracellular signal-regulated kinase 1/2, Jun N-terminal kinase, and p38 mitogen-activated protein kinases in asthmatic airways. J Allergy Clin Immunol 2008;121:893–902 e892.
  • Wouters EF, Reynaert NL, Dentener MA, Vernooy JH. Systemic and local inflammation in asthma and chronic obstructive pulmonary disease: is there a connection? Proc Am Thorac Soc 2009;6:638–647.
  • GINA: Global strategy for asthma management and prevention. 2012. Available from http://www.ginasthma.org/documents/5/documents_variants/37.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.